Sodium Thiosulfate Reduces Acute Kidney Injury in Patients Undergoing Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy with Cisplatin: A Single-Center Observational Study

[1]  M. Pocard,et al.  Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. , 2021, The Lancet. Oncology.

[2]  Michael E. Egger,et al.  Enhanced recovery after surgery is safe for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. , 2020, American journal of surgery.

[3]  B. Rau,et al.  Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS®) Society Recommendations - Part I: Preoperative and intraoperative management. , 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[4]  B. Rau,et al.  Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced Recovery After Surgery (ERAS®) Society Recommendations - Part II: Postoperative management and special considerations. , 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[5]  D. Doyle,et al.  American Society of Anesthesiologists Classification , 2020 .

[6]  A. Friggeri,et al.  Sodium thiosulfate protects from renal impairement following hyperthermic intraperitoneal chemotherapy (HIPEC) with Cisplatin , 2020, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[7]  R. Bleday,et al.  Cytoreductive Surgery and HIPEC in an Enhanced Recovery After Surgery Program: A Feasibility Study. , 2019, The Journal of surgical research.

[8]  B. Pockaj,et al.  Implementation of an Enhanced Recovery After Surgery (ERAS) Program is Associated with Improved Outcomes in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy , 2019, Annals of Surgical Oncology.

[9]  G. Salti,et al.  Acute kidney injury increases the rate of major morbidities in cytoreductive surgery and HIPEC , 2018, Annals of medicine and surgery.

[10]  Mike Hernandez,et al.  Identification of risk factors associated with postoperative acute kidney injury after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a retrospective study , 2018, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[11]  B. Morland,et al.  Sodium Thiosulfate for Protection from Cisplatin‐Induced Hearing Loss , 2018, The New England journal of medicine.

[12]  N. Aaronson,et al.  Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer , 2018, The New England journal of medicine.

[13]  B. Rau,et al.  Peritoneal metastases of rare carcinomas treated with cytoreductive surgery and HIPEC – A single center case series , 2017, Annals of medicine and surgery.

[14]  K. Soo,et al.  Acute kidney injury in ovarian cancer patients undergoing cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy , 2017, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[15]  B. Pollock,et al.  Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. , 2017, The Lancet. Oncology.

[16]  A. Azzam,et al.  The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery , 2014, Renal failure.

[17]  S. Msika,et al.  Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[18]  W. Richards,et al.  Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. , 2009, The Journal of thoracic and cardiovascular surgery.

[19]  Lingyun Ji,et al.  Sodium Thiosulfate Administered Six Hours after Cisplatin Does Not Compromise Antineuroblastoma Activity , 2008, Clinical Cancer Research.

[20]  John A Kellum,et al.  Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury , 2007, Critical care.

[21]  N. Demartines,et al.  Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey , 2004, Annals of Surgery.

[22]  H. van Tinteren,et al.  Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Mocellin,et al.  Pharmacokinetics of intraperitoneal cisplatin and doxorubicin. , 2003, Surgical oncology clinics of North America.

[24]  E. Zuhowski,et al.  Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity. , 2000, Clinical Cancer Research.

[25]  P. Sugarbaker.  Management of peritoneal-surface malignancy: the surgeon’s role , 1999, Langenbeck's Archives of Surgery.

[26]  R. Verheijen,et al.  Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  H. Kampinga,et al.  Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells. , 1997, British Journal of Cancer.

[28]  P. Sugarbaker,et al.  Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. , 1996, Cancer treatment and research.

[29]  O. Dalesio,et al.  Phase II trial for intraperitoneal cisplatin plus intravenous sodium thiosulphate in advanced ovarian carcinoma patients with minimal residual disease after cisplatin-based chemotherapy--a phase II study of the EORTC Gynaecological Cancer Cooperative Group. , 1994, European journal of cancer.

[30]  O. Tanizawa,et al.  Neutralizing effect of sodium thiosulfate on antitumor efficacy of cisplatin for human carcinoma xenografts in nude mice. , 1991, Gynecologic oncology.

[31]  S. Yoshida,et al.  [Effect of sodium thiosulfate on the antitumor effect and nephrotoxicity of CDDP in human gastric cancer transplanted in nude mice]. , 1989, Gan to kagaku ryoho. Cancer & chemotherapy.

[32]  S. Howell,et al.  High-dose cisplatin with sodium thiosulfate protection. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.